The presence of pulmonary hypertension in children with a congenital heart
defect carries the risk of considerable problems of management immediately
after corrective surgery. To evaluate whether inhaled nitric oxide (NO) com
plements other routine therapeutic measures to lower pulmonary artery press
ure, 28 infants and children (ages, 0.85 +/- 0.19 years) with this conditio
n were studied within the first few days after surgery. Hemodynamics and/or
oxygen saturations were significantly improved by NO inhalation (initial c
oncentration, 15 +/- 1.8 ppm) in 27 patients (96%). Mean pulmonary arterial
pressure (PAP) declined significantly from 45 +/- 5.8 to 27 +/- 3.1 mmHg,
whereas there were significant increases in mean systemic arterial pressure
(55 +/- 1.9 to 59 +/- 1.8 mmHg) and arterial oxygen saturation (SaO(2), 90
+/- 1.9 to 97 +/- 1.1%). The changes in PAP (ED50: 0.29 +/- 0.07 ppm NO) a
nd SaO(2) (ED50: 0.21 +/- 0.04 ppm NO) were dose-dependent with no signific
ant difference in ED,, values. The NO-induced pulmonary vasodilation was in
dependent of the concomitant reduction in arterial carbon dioxide tension.
In a case-control study of a subgroup of 18 patients and 35 matched control
s, inhaled NO significantly reduced the frequency of pulmonary hypertensive
crises by 83% and lowered the mortality rate from 14.2% to zero. During lo
w-dose NO inhalation there was no detectable formation of methemoglobin or
significant production of nitric dioxide (NO,), and no disturbance of plate
let aggregation or leukocyte adhesion. It is concluded that in children und
ergoing cardiac bypass surgery, low-dose inhaled NO improves hemodynamics a
nd oxygenation, and reduces the frequency, severity, and mortality of pulmo
nary hypertensive crises during perioperative intensive care. We recommend
a dose range of 1-10 ppm NO for routine use, and an absolute upper dose lim
it of 40 ppm NO to avoid potential adverse side effects. (C) 1998 Elsevier
Science Ireland Ltd. All rights reserved.